KCNJ14 knockdown significantly inhibited the proliferation and migration of colorectal cells.
Biological target
Colorectal cancer
KCNJ14
Methylation
Prognosis
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
30
09
2021
accepted:
25
07
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
This study attempted to verify the potential of KCNJ14 as a biomarker in colorectal cancer (CRC). Data on transcriptomics and DNA methylation and the clinical information of CRC patients were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. Biological information analysis methods were conducted to determine the role of KCNJ14 in the prognosis, diagnosis, immune cell infiltration, and regulation mechanism of CRC patients. The effect of KCNJ14 on the proliferation and migration of HCT116 and SW480 CRC cell lines was verified by in vitro experiments (MTT, colony-forming, wound healing, and transwell assays). Western blotting was performed to detect the effect of KCNJ14 on the levels of mTOR signalling pathway-related proteins. KCNJ14 expression was remarkably increased in CRC tissues and cell lines, which reduced the overall survival time of patients. KCNJ14 mRNA was negatively regulated by its methylation site cg17660703, which can also endanger the prognosis of patients with CRC. Functional enrichment analysis suggested that KCNJ14 is involved in the mTOR, NOD-like receptor, and VEGF signalling pathways. KCNJ14 expression was positively correlated with the number of CD4 + T cells and negatively correlated with that of CD8 + T cells in the immune microenvironment. KCNJ14 knockdown significantly reduced not only the proliferation and migration of CRC cell lines but also the levels of mTOR signalling pathway-related proteins. This study not only increases the molecular understanding of KCNJ14 but also provides a potentially valuable biological target for the treatment of colorectal cancer.
Sections du résumé
BACKGROUND
This study attempted to verify the potential of KCNJ14 as a biomarker in colorectal cancer (CRC).
METHODS
Data on transcriptomics and DNA methylation and the clinical information of CRC patients were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. Biological information analysis methods were conducted to determine the role of KCNJ14 in the prognosis, diagnosis, immune cell infiltration, and regulation mechanism of CRC patients. The effect of KCNJ14 on the proliferation and migration of HCT116 and SW480 CRC cell lines was verified by in vitro experiments (MTT, colony-forming, wound healing, and transwell assays). Western blotting was performed to detect the effect of KCNJ14 on the levels of mTOR signalling pathway-related proteins.
RESULTS
KCNJ14 expression was remarkably increased in CRC tissues and cell lines, which reduced the overall survival time of patients. KCNJ14 mRNA was negatively regulated by its methylation site cg17660703, which can also endanger the prognosis of patients with CRC. Functional enrichment analysis suggested that KCNJ14 is involved in the mTOR, NOD-like receptor, and VEGF signalling pathways. KCNJ14 expression was positively correlated with the number of CD4 + T cells and negatively correlated with that of CD8 + T cells in the immune microenvironment. KCNJ14 knockdown significantly reduced not only the proliferation and migration of CRC cell lines but also the levels of mTOR signalling pathway-related proteins.
CONCLUSIONS
This study not only increases the molecular understanding of KCNJ14 but also provides a potentially valuable biological target for the treatment of colorectal cancer.
Identifiants
pubmed: 36100894
doi: 10.1186/s12920-022-01351-4
pii: 10.1186/s12920-022-01351-4
pmc: PMC9472386
doi:
Substances chimiques
Kir2.4 channel
0
Potassium Channels, Inwardly Rectifying
0
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Informations de copyright
© 2022. The Author(s).
Références
Oncotarget. 2017 Jun 6;8(23):37681-37693
pubmed: 28445150
Cell Cycle. 2020 Jul;19(13):1632-1640
pubmed: 32436804
Br J Nutr. 2021 Dec 14;126(11):1611-1625
pubmed: 33583435
Cancer Res. 2013 Feb 1;73(3):1056-62
pubmed: 23269273
Cell Signal. 2019 Sep;61:86-92
pubmed: 31121307
Int J Colorectal Dis. 2012 Dec;27(12):1579-86
pubmed: 22710688
Acta Histochem. 2019 Jul;121(5):657-663
pubmed: 31153587
Cell Host Microbe. 2013 Aug 14;14(2):207-15
pubmed: 23954159
Compr Physiol. 2018 Sep 14;8(4):1463-1511
pubmed: 30215858
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
Mol Cancer. 2015 Mar 12;14:59
pubmed: 25880778
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
Front Immunol. 2019 Dec 17;10:2936
pubmed: 31921188
Med Chem. 2016;12(7):613-620
pubmed: 26951145
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Oncotarget. 2012 Apr;3(4):462-74
pubmed: 22577155
Health Rep. 2018 Dec 19;29(12):21-25
pubmed: 30566206
Int J Biol Sci. 2021 Jul 25;17(12):3188-3208
pubmed: 34421359
Nat Genet. 2009 Feb;41(2):178-186
pubmed: 19151715
Cancers (Basel). 2019 Jun 07;11(6):
pubmed: 31181683
Front Immunol. 2019 Oct 17;10:2368
pubmed: 31681276
Cell Death Dis. 2015 Jul 02;6:e1801
pubmed: 26136074
Curr Drug Targets. 2019;20(12):1217-1226
pubmed: 31215384
Mamm Genome. 2000 Mar;11(3):247-9
pubmed: 10723734
J Exp Clin Cancer Res. 2019 Jun 18;38(1):265
pubmed: 31215501
Biochem Biophys Res Commun. 2020 Feb 12;522(3):676-683
pubmed: 31785816
Genet Test Mol Biomarkers. 2015 Nov;19(11):617-22
pubmed: 26383988
EMBO Mol Med. 2020 Jan 9;12(1):e10681
pubmed: 31793740
Mol Genet Genomic Med. 2020 Jul;8(7):e1255
pubmed: 32396280
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Genomics. 2020 Nov;112(6):4808-4816
pubmed: 32882327
PLoS One. 2014 Feb 06;9(2):e87761
pubmed: 24516561
Anticancer Agents Med Chem. 2019;19(10):1293-1312
pubmed: 30727917
Eur J Pharmacol. 2002 Jan 25;435(2-3):125-33
pubmed: 11821018
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Clin Gastroenterol Hepatol. 2012 Jun;10(6):639-45
pubmed: 22289873
World J Gastroenterol. 2015 Sep 21;21(35):10072-9
pubmed: 26401072
Front Oncol. 2020 Oct 20;10:579692
pubmed: 33194705
Endocr Relat Cancer. 2009 Sep;16(3):939-52
pubmed: 19502451
J Exp Ther Oncol. 2004 Jul;4(2):161-6
pubmed: 15500011
Thromb Res. 2019 Aug;180:87-97
pubmed: 31271975
Front Surg. 2021 Jun 16;8:681721
pubmed: 34222322
Physiol Res. 2013;62(1):95-105
pubmed: 23173681